SILENCE THER. (SLN)

 

SLN Share PerformanceMore

52 week high135.00 21/04/16
52 week low82.00 02/03/17
52 week change -25.50 (-22.44%)
4 week volume552,330 01/03/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Notice of Results

RNS Number: 8042Y Silence Therapeutics PLC 08 March 2017 Notice of Results 8 March 2017 London, 8 March 2017 - Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, plans to announce its Preliminary Result...

Silence update on stake in Arrowhead Pharmaceuticals

Silence Therapeutics has issued an update to its announcement on 9 January regarding the acquisition of a minority stake ...

Minority Stake in Arrowhead Pharmaceuticals

RNS Number: 1602U Silence Therapeutics PLC 13 January 2017 Minority stake in Arrowhead Pharmaceuticals 13 th January 2017 London, 13 th January 2017 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, p...

Silence Therapeutics acquires minority stake in Arrowhead

Silence Therapeutics has acquired a stake, on-market, in Arrowhead Pharmaceuticals, Inc. of 6.01m shares, or 8.4% of the co...

Acquisition of Minority Stake in Arrowhead

RNS Number: 6001T Silence Therapeutics PLC 09 January 2017 Acquisition of minority stake in Arrowhead Pharmaceuticals 9 th January 2017 London, 9 th January 2017 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet m...

Silence Therapeutics notes Quark arbitration resolution

Silence Therapeutics has reached a settlement in the arbitration process with Quark Pharmaceuticals. Silence and its license...

Silence announces Quark arbitration resolution

RNS Number: 2913S Silence Therapeutics PLC 20 December 2016 Quark arbitration resolution 20 December 2016 London, 20 December 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, is pleased to anno...

CRISPR/Cas9 Gene Editing Data

RNS Number: 1506P Silence Therapeutics PLC 15 November 2016 CRISPR/Cas9 Gene Editing Data A single-particle RNA based approach to in vivo CRISPR/Cas9 gene editing London, 15 November 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment o...

Fundamental DataMore

EPS-10.4
Dividend yield0 %

Latest discussion posts More

Users' HoldingsMore

Users who hold SILENCE THER. also hold..
LLOYDS GRP.28%
BP23%
TESCO17%
ROYAL BANK SCOT17%
BARCLAYS17%

Codes & Symbols

ISINGB00B9GTXM62
SymbolsSLN, LSE:SLN, SLN.L, SLN:LN, LON:SLN, XLON:SLN